Interleukin-18 Plays a Positive Feedback Activity to Natural Killer-Like B Cells in Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure

Liu, Ye; Xing, Meng; Wang, Chao; Zhang, Ye; Hua, Wen-Wen; Zhi, Wang

doi:10.1089/vim.2021.0164

Cited by 8 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NKB cells have phenotypes of NK cells and B cells. NKB cells exhibit immunomodulatory functions in eliminating microbial infection and inflammation by secreting interleukin (IL)-12 and IL-18 [ 82 ]. IL-18 is a decisive factor in controlling Th1/Th2 balance during antiviral responses [ 83 ].…”

Section: Interleukin-18mentioning

confidence: 99%

“…The study found that low concentrations of IL-18 did not induce elevated NF- κ B phosphorylation, which may be due to insufficient neutralization of IL-18BP by IL-18. Conversely, high concentrations (10 ng/mL) of IL-18 might completely block the activity of IL-18BP and further increase phosphorylated NF- κ B, ultimately inducing NKB cell activity in HBV-ACLF, suggesting that in HBV-ACLF, IL-18 has potential positive feedback activity in regulating NKB cells during progression [ 82 ]. Clinical trials showed that compared with CHB, asymptomatic HBV carriers, and control group, the percentage of NKB cells in lymphocytes and the level of IL-18 in HBV-ACLF patients were significantly increased [ 82 ].…”

Section: Interleukin-18mentioning

confidence: 99%

“…Conversely, high concentrations (10 ng/mL) of IL-18 might completely block the activity of IL-18BP and further increase phosphorylated NF- κ B, ultimately inducing NKB cell activity in HBV-ACLF, suggesting that in HBV-ACLF, IL-18 has potential positive feedback activity in regulating NKB cells during progression [ 82 ]. Clinical trials showed that compared with CHB, asymptomatic HBV carriers, and control group, the percentage of NKB cells in lymphocytes and the level of IL-18 in HBV-ACLF patients were significantly increased [ 82 ]. Elevated NKB cells and IL-18 may be important indicators of poor prognosis in patients with HBV-ACLF [ 82 ].…”

Section: Interleukin-18mentioning

confidence: 99%

“…Clinical trials showed that compared with CHB, asymptomatic HBV carriers, and control group, the percentage of NKB cells in lymphocytes and the level of IL-18 in HBV-ACLF patients were significantly increased [ 82 ]. Elevated NKB cells and IL-18 may be important indicators of poor prognosis in patients with HBV-ACLF [ 82 ]. The increased proportion of NKB cells and the increased level of IL-18 in peripheral blood have good prognostic value on the survival status of HBV-ACLF.…”

Section: Interleukin-18mentioning

confidence: 99%

“…The increased proportion of NKB cells and the increased level of IL-18 in peripheral blood have good prognostic value on the survival status of HBV-ACLF. It indicates that IL-18 may be a hallmark cytokine secreted by NKB cells for regulating the inflammatory response of HBV-ACLF [ 82 ]. Studies show that IL-18-607A/C functional polymorphism is associated with susceptibility to an enhanced form of HBV DNA replication in chronic infection [ 83 ].…”

Section: Interleukin-18mentioning

confidence: 99%

See 4 more Smart Citations

Serum Interleukins as Potential Prognostic Biomarkers in HBV-Related Acute-on-Chronic Liver Failure

Zhang

Gou

et al. 2022

Mediators of Inflammation

View full text Add to dashboard Cite

Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is relatively common in China and has complex pathogenesis, difficult clinical treatment, and poor prognosis. Immune status is an important factor affecting ACLF prognosis. Interleukins are a family of secreted lymphocyte factors that interact with a host of cell types including immune cells. These signaling molecules play important roles in transmitting information; regulating immune cells; mediating the activation, proliferation, and differentiation of T and B cells; and modulating inflammatory responses. Many studies have investigated the correlation between interleukin expression and the prognosis of HBV-ACLF. This review focuses on the potential use of interleukins as prognostic biomarkers in HBV-ACLF. References were mainly identified through PubMed and CNKI search, including relevant studies published until December 2021. We have summarized reports of several promising diagnostic interleukin biomarkers that predict susceptibility to HBV-ACLF. The use of biomarkers to understand early prognosis can help devise different therapeutic measures and improve patient survival. Ongoing research on prognostic biomarkers of HBV-ACLF is promising, and future preclinical and clinical studies are warranted.

show abstract

Section: Interleukin-18mentioning

confidence: 99%

Section: Interleukin-18mentioning

confidence: 99%